| scholarly article | Q13442814 |
| P356 | DOI | 10.1001/ARCHPSYC.1996.01830110029004 |
| P698 | PubMed publication ID | 8911222 |
| P2093 | author name string | Heninger GR | |
| Cohen DJ | |||
| McDougle CJ | |||
| Aghajanian GK | |||
| Price LH | |||
| Naylor ST | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism | Q38404 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 993-1000 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Effects of tryptophan depletion in drug-free adults with autistic disorder | |
| P478 | volume | 53 |
| Q50312788 | A neurobehavioral examination of individuals with high-functioning autism and Asperger's disorder using a fronto-striatal model of dysfunction |
| Q47783539 | A pilot study of serotonergic modulation after long-term administration of oxytocin in autism spectrum disorder |
| Q45189223 | A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism |
| Q37366340 | A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders |
| Q28384969 | Acute dietary tryptophan manipulation differentially alters social behavior, brain serotonin and plasma corticosterone in three inbred mouse strains |
| Q34558995 | Acute tryptophan depletion. Part II: clinical effects and implications |
| Q46568974 | Altered amino acid excretion in children with autism |
| Q40397762 | Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity. |
| Q59263464 | Analysis of amino acids in autism spectrum disorders |
| Q99548991 | Analyzing the Potential Biological Determinants of Autism Spectrum Disorder: From Neuroinflammation to the Kynurenine Pathway |
| Q22241891 | Antipsychotics in the treatment of autism |
| Q39403381 | Aspects of Tryptophan and Nicotinamide Adenine Dinucleotide in Immunity: A New Twist in an Old Tale |
| Q89537222 | Assessments of Amino Acids, Ammonia and Oxidative Stress Among Cohort of Egyptian Autistic Children: Correlations with Electroencephalogram and Disease Severity |
| Q34013736 | Association of transcription factor gene LMX1B with autism |
| Q34294006 | Association of tryptophan 2,3 dioxygenase gene polymorphism with autism |
| Q34470381 | Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. |
| Q38705661 | Associations of endocrine stress-related gene polymorphisms with risk of autism spectrum disorders: Evidence from an integrated meta-analysis |
| Q89477422 | Autism and Gut-Brain Axis: Role of Probiotics |
| Q35092611 | Autism associated gene, engrailed2, and flanking gene levels are altered in post-mortem cerebellum |
| Q36219642 | Autism spectrum disorders: emerging pharmacotherapy |
| Q30607088 | Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy |
| Q50418445 | Autism: xenobiotic influences |
| Q92206251 | Autistic spectrum disorders |
| Q38816381 | Body fluid levels of neuroactive amino acids in autism spectrum disorders: a review of the literature. |
| Q59326917 | Brain hyperserotonemia causes autism-relevant social deficits in mice |
| Q36275091 | Chromatographic determination of harmalans in the urine of autistic children. |
| Q22252305 | Complementary and alternative medicine treatments for children with autism spectrum disorders |
| Q38299791 | Convergence of circuit dysfunction in ASD: a common bridge between diverse genetic and environmental risk factors and common clinical electrophysiology |
| Q36411547 | Correlates of psychomotor symptoms in autism |
| Q36371306 | Current perspectives on the genetic analysis of autism. |
| Q48266971 | Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children |
| Q37929093 | Dystrophic serotonin axons in postmortem brains from young autism patients |
| Q36727667 | Early pharmacological treatment of autism: a rationale for developmental treatment |
| Q34073325 | Emerging drugs for the treatment of symptoms associated with autism spectrum disorders |
| Q38799214 | Endosomal system genetics and autism spectrum disorders: A literature review |
| Q24535713 | Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. |
| Q48173034 | Evidence of altered energy metabolism in autistic children |
| Q24645089 | Examination of association of genes in the serotonin system to autism |
| Q90230119 | Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder |
| Q50302866 | Family-based association study of TPH1 and TPH2 polymorphisms in autism |
| Q33794328 | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
| Q93050785 | Gender-Specific Effect of 5-HT and 5-HIAA on Threshold Level of Behavioral Symptoms and Sex-Bias in Prevalence of Autism Spectrum Disorder |
| Q36921232 | Genetic and pharmacological manipulations of the serotonergic system in early life: neurodevelopmental underpinnings of autism-related behavior |
| Q56672658 | Glyphosate’s Suppression of Cytochrome P450 Enzymes and Amino Acid Biosynthesis by the Gut Microbiome: Pathways to Modern Diseases |
| Q47698588 | How important is tryptophan in human health? |
| Q50302100 | Hyperserotonemia in adults with autistic disorder. |
| Q46120077 | Hyperserotonemia in autism: activity of 5HT-associated platelet proteins. |
| Q28307190 | Hyperserotoninemia and altered immunity in autism |
| Q37774097 | Immune dysfunction in autism: a pathway to treatment |
| Q32063177 | Impairment of dentato-thalamo-cortical pathway in autistic men: language activation data from positron emission tomography |
| Q50312936 | Increased growth hormone response to sumatriptan challenge in adult autistic disorders |
| Q88435012 | Investigating Plasma Amino Acids for Differentiating Individuals with Autism Spectrum Disorder and Typically Developing Peers |
| Q37715771 | Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism |
| Q35151007 | MAOA, DBH, and SLC6A4 variants in CHARGE: a case-control study of autism spectrum disorders |
| Q30623213 | Medication treatment in subjects with autistic spectrum disorders |
| Q28390641 | Mice genetically depleted of brain serotonin display social impairments, communication deficits and repetitive behaviors: possible relevance to autism |
| Q38793435 | Microbiome and nutrition in autism spectrum disorder: current knowledge and research needs |
| Q37449787 | Modeling rare gene variation to gain insight into the oldest biomarker in autism: construction of the serotonin transporter Gly56Ala knock-in mouse |
| Q59791335 | Molecular Pathology and Pharmacological Treatment of Autism Spectrum Disorder-Like Phenotypes Using Rodent Models |
| Q38268023 | Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach |
| Q24630108 | My experience learning about autism |
| Q33617477 | N-ethylmaleimide-sensitive factor interacts with the serotonin transporter and modulates its trafficking: implications for pathophysiology in autism |
| Q22248039 | Neurobiological Correlates of Autism: A Review of Recent Research |
| Q38342576 | Neuron membrane trafficking and protein kinases involved in autism and ADHD. |
| Q35102732 | Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity |
| Q44315647 | Obsessive compulsive behaviour in autism--towards an autistic-obsessive compulsive syndrome? |
| Q50309956 | Pathophysiology of autism: current opinions |
| Q30472853 | Perinatal antidepressant exposure alters cortical network function in rodents |
| Q36443014 | Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan |
| Q34374344 | Pharmacotherapy of pervasive developmental disorders in children and adolescents. |
| Q34228445 | Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies |
| Q34403081 | Possible association between autism and variants in the brain-expressed tryptophan hydroxylase gene (TPH2). |
| Q33696362 | Psychopharmacotherapy in children and adults with intellectual disability |
| Q64103670 | Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders |
| Q37661363 | Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala |
| Q33837479 | Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. |
| Q27308143 | Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice |
| Q42135924 | Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia |
| Q94595603 | Serotonin differentially modulates the temporal dynamics of the limbic response to facial emotions in male adults with and without autism spectrum disorder (ASD): a randomised placebo-controlled single-dose crossover trial |
| Q38326506 | Serotonin dysregulation in Fragile X Syndrome: implications for treatment |
| Q38089714 | Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy |
| Q35851031 | Serotonin transporter gene polymorphisms and hyperserotonemia in autistic disorder |
| Q38310482 | Studying the neurobiology of human social interaction: Making the case for ecological validity |
| Q33760635 | Symptom provocation studies in psychiatric disorders: scientific value, risks, and future |
| Q34177643 | Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders |
| Q36258557 | Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders |
| Q35577128 | The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. |
| Q28508280 | The disruption of Celf6, a gene identified by translational profiling of serotonergic neurons, results in autism-related behaviors |
| Q34225636 | The effects of tryptophan depletion on mood and psychiatric symptoms |
| Q36477123 | The importance of catatonia and stereotypies in autistic spectrum disorders |
| Q34871941 | The intense world syndrome--an alternative hypothesis for autism |
| Q36397920 | The minicolumnopathy of autism: A link between migraine and gastrointestinal symptoms |
| Q34699035 | The neurobiology of autism |
| Q42729995 | The pathophysiology of restricted repetitive behavior |
| Q44511471 | The platelet-poor plasma 5-HT response to carbohydrate rich meal administration in adult autistic patients compared with normal controls. |
| Q35937022 | The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning |
| Q35098779 | The serotonergic anatomy of the developing human medulla oblongata: implications for pediatric disorders of homeostasis |
| Q30484882 | The serotonergic system: its role in pathogenesis and early developmental treatment of autism |
| Q28391614 | The serotonin system in autism spectrum disorder: From biomarker to animal models |
| Q30416166 | Towards large-cohort comparative studies to define the factors influencing the gut microbial community structure of ASD patients |
| Q95825852 | Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons |
| Q41689631 | Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. |
| Q33891726 | Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report |
| Q57295974 | p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse |
Search more.